Comparison Overview

Viatris

VS

Hikma Pharmaceuticals

Viatris

Last Update: 2025-12-10
Between 750 and 799

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.twitter.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 16,525
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB
Last Update: 2025-12-11
Between 750 and 799

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,222
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/viatris.jpeg
Viatris
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Viatris
100%
Compliance Rate
0/4 Standards Verified
Hikma Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Viatris in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2025.

Incident History — Viatris (X = Date, Y = Severity)

Viatris cyber incidents detection timeline including parent company and subsidiaries

Incident History — Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/viatris.jpeg
Viatris
Incidents

No Incident

https://images.rankiteo.com/companyimages/hikma-pharmaceuticals.jpeg
Hikma Pharmaceuticals
Incidents

No Incident

FAQ

Viatris company demonstrates a stronger AI Cybersecurity Score compared to Hikma Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Hikma Pharmaceuticals company has disclosed a higher number of cyber incidents compared to Viatris company.

In the current year, Hikma Pharmaceuticals company and Viatris company have not reported any cyber incidents.

Neither Hikma Pharmaceuticals company nor Viatris company has reported experiencing a ransomware attack publicly.

Neither Hikma Pharmaceuticals company nor Viatris company has reported experiencing a data breach publicly.

Neither Hikma Pharmaceuticals company nor Viatris company has reported experiencing targeted cyberattacks publicly.

Neither Viatris company nor Hikma Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither Viatris nor Hikma Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

Viatris company has more subsidiaries worldwide compared to Hikma Pharmaceuticals company.

Viatris company employs more people globally than Hikma Pharmaceuticals company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Viatris nor Hikma Pharmaceuticals holds SOC 2 Type 1 certification.

Neither Viatris nor Hikma Pharmaceuticals holds SOC 2 Type 2 certification.

Neither Viatris nor Hikma Pharmaceuticals holds ISO 27001 certification.

Neither Viatris nor Hikma Pharmaceuticals holds PCI DSS certification.

Neither Viatris nor Hikma Pharmaceuticals holds HIPAA certification.

Neither Viatris nor Hikma Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N